Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

695 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C.
Siebert U, Sroczynski G, Rossol S, Wasem J, Ravens-Sieberer U, Kurth BM, Manns MP, McHutchison JG, Wong JB; German Hepatitis C Model (GEHMO) Group; International Hepatitis Interventional Therapy (IHIT) Group. Siebert U, et al. Gut. 2003 Mar;52(3):425-32. doi: 10.1136/gut.52.3.425. Gut. 2003. PMID: 12584228 Free PMC article. Clinical Trial.
Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Federal Ministry of Health and Social Security.
Siebert U, Sroczynski G; German Hepatitis C Model GEHMO Group; HTA Expert Panel on Hepatitis C. Siebert U, et al. Int J Technol Assess Health Care. 2005 Winter;21(1):55-65. doi: 10.1017/s0266462305050075. Int J Technol Assess Health Care. 2005. PMID: 15736515 Review.
Using competence network collaboration and decision-analytic modeling to assess the cost-effectiveness of interferon alpha-2b plus ribavirin as initial treatment of chronic hepatitis C in Germany.
Siebert U, Sroczynski G, Wasem J, Greiner W, Ravens-Sieberer U, Aidelsburger P, Kurth BM, Bullinger M, von der Schulenburg JM, Wong JB, Rossol S. Siebert U, et al. Eur J Health Econ. 2005 Jun;6(2):112-23. doi: 10.1007/s10198-005-0280-7. Eur J Health Econ. 2005. PMID: 15902546
Cost-effectiveness of primarily human papillomavirus-based cervical cancer screening in settings with currently established Pap screening: a systematic review commissioned by the German Federal Ministry of Health.
Mühlberger N, Sroczynski G, Esteban E, Mittendorf T, Miksad RA, Siebert U. Mühlberger N, et al. Among authors: siebert u. Int J Technol Assess Health Care. 2008 Spring;24(2):184-92. doi: 10.1017/S0266462308080264. Int J Technol Assess Health Care. 2008. PMID: 18400122 Review.
Market uptake of new antiviral drugs for the treatment of hepatitis C.
Lettmeier B, Mühlberger N, Schwarzer R, Sroczynski G, Wright D, Zeuzem S, Siebert U. Lettmeier B, et al. Among authors: siebert u. J Hepatol. 2008 Oct;49(4):528-36. doi: 10.1016/j.jhep.2008.04.021. Epub 2008 Jun 2. J Hepatol. 2008. PMID: 18682313
695 results